<DOC>
	<DOCNO>NCT01679184</DOCNO>
	<brief_summary>Donor-Specific Antibody ( DSA ) ( HLA ) level non-HLA antibody level recipient prior live kidney transplantation randomize individual desensitization protocol order evaluate shift occur Luminex XM-One assay treatment 6 month post transplant . If desensitization need prior transplantation individual negative crossmatch positive DSA and/or XM-one - patient evaluate clinically routine lab test ( serum creatinine level , spot urine protein spot urine creatinine level ) well protocol biopsy evaluation .</brief_summary>
	<brief_title>XM-One Study Living Donor Program</brief_title>
	<detailed_description>1 . Rates acute rejection include subclinical rejection - acute T cell mediate ( cellular ) rejection , antibody mediate acute rejection , chronic antibody-associated injury ( i.e . : Transplant Glomerulopathy , Chronic allograft arteriopathy ) group . 2 . Evaluation endothelial cell activation injury biopsy check marker endothelial cell activation injury ( intercellular adhesion molecule-1 , ICAM-1/CD54 ; vascular cell adhesion molecule-1 , VCAM-1/CD106 ; E-selectin , ELAM-1/CD62E ) two-color stain tissue classical endothelial marker ( CD34 Factor VIII ) . 3 . Measurement serum/plasma level TNF-alpha VEGF decrease level protein C protein S circulation , assessment graft vascular perturbation . 4 . Circulating Endothelial Cells ( CECs ) measure flow cytometry marker endothelial cell activation .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Recipients receive deceased donor transplant . Living donor transplant Tcell flow crossmatch positive . HIV , Hepatitis C B positive patient . Pregnant woman child exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>